A modified fragment of human growth hormone spanning amino acids 176–191. Lipolysis is stimulated and lipogenesis inhibited, without the side effects that accompany full growth hormone: IGF-1 does not rise, glucose metabolism is unaffected, and insulin resistance does not follow.

Long-acting lipidated amylin analog that acts at both the amylin and calcitonin receptors, aimed at weight management and type 2 diabetes. In the CagriSema combination, phase 3 trials report 22.7% weight loss.

Synthetic analog of growth hormone releasing hormone whose short half-life leaves GH secretion pulsatile, in patterns resembling natural physiology. Where CJC-1295 with DAC elevates GH continuously, this version keeps the natural pulsatility.

Growth hormone releasing hormone, modified with albumin-binding technology so that duration extends. Binding of the DAC to albumin lengthens half-life and holds GHRH receptor stimulation continuous.

Polypeptide hormone of 191 amino acids, also called somatropin, with FDA approval covering growth hormone deficiency in children and adults, HIV-associated wasting, and other conditions. Anabolic effects arrive by two routes, direct and indirect through IGF-1.

The segment of human growth hormone responsible for fat burning: amino acids 176 through 191 within the full GH molecule. It stimulates lipolysis and inhibits lipogenesis, leaving out the effects on growth and on insulin that come with HGH at full length. Adding an N-terminal tyrosine residue to this fragment gives AOD-9604.

Selective GHRP that raises natural GH production from the pituitary while disruption of cortisol and prolactin stays minimal. It is known for a clean safety profile and for consistent GH pulses, free of the significant side effects common to other growth hormone releasing peptides.

Triple hormone receptor agonist whose targets are the glucagon, GIP, and GLP-1 receptors. At 48 weeks, phase II trials recorded weight loss of 24.2%, the highest yet recorded for obesity medications.

GLP-1 receptor agonist, long-acting, with approval for chronic weight management and type 2 diabetes. Significant efficacy has been demonstrated across more than 17,000 trial participants, by way of glycemic control and appetite suppression. Weekly dosing is convenient, enabled by the 7-day half-life.

Analog of human growth hormone-releasing hormone, synthetic, 29 amino acids long. Growth hormone production rises naturally under it while the physiological pulsatile pattern holds. The FDA approved it in 1997 for GH deficiency in children; discontinuation followed in 2008, for manufacturing reasons and not safety concerns.

Synthetic GHRH analog with FDA approval, designed for HIV-associated lipodystrophy. Visceral fat is targeted selectively — clinical trials record 15–20% visceral fat reduction — while subcutaneous fat is preserved.

Dual receptor agonist with FDA approval for type 2 diabetes and chronic weight management. Efficacy runs above that of single-mechanism alternatives, with body weight reduced 15–22% in clinical trials. As the first-in-class dual GIP/GLP-1 agonist it delivers metabolic benefits beyond those of GLP-1-only medications.

Synthetic growth hormone secretagogue that prompts the pituitary gland to release growth hormone. Among the GHRP family it ranks with the most potent, 2–3 times as effective as GHRP-6 at stimulating GH release. Its original role was diagnostic, for growth hormone deficiency; the mechanism is mimicry of ghrelin and binding at the GHS-R1a receptor.

Synthetic growth hormone secretagogue that prompts the pituitary gland to release growth hormone. It was among the first GHRPs developed and binds the ghrelin receptor (GHS-R1a). Rather than supply GH directly as an injection would, it raises the body's own GH production while negative feedback mechanisms stay balanced. Appetite stimulation is its noted potent effect.

Among synthetic growth hormone secretagogues, one of the most potent available. Binding at the GHS-R1a receptor of the hypothalamus and pituitary mimics ghrelin and releases GH. With GHRH the effect is synergistic: the GH response comes out greater than the arithmetic sum of the two given separately. Cardioprotective properties unique to it are mediated by the CD36 receptor.

Dual GLP-1 and glucagon receptor agonist, first in its class, pairing appetite suppression with stimulated thermogenesis. Phase 3 trials showed it superior to semaglutide on weight loss and glycemic control.

The first oral non-peptide GLP-1 to complete Phase 3 trials. Substantial weight loss comes without injections, refrigeration, or dietary restrictions, and clinical evidence puts the reduction at 12.4% by 72 weeks.

Investigational dual receptor agonist for metabolic disease, working through balanced activation of GLP-1R and GCGR. Phase 2/3 clinical trials show superior weight loss and efficacy in MASH treatment.

Chimeric peptidomimetic aimed at the vasculature of adipose tissue: it binds prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro-apoptotic D-(KLAKLAK)2 motif. Obese primates lost fat rapidly and insulin resistance improved, but kidney safety signals stopped development after Phase 1.